Paysign, Inc. (NASDAQ:PAYS – Get Free Report)’s stock price hit a new 52-week high during trading on Wednesday. The company traded as high as $15.62 and last traded at $15.48, with a volume of 799,987 shares trading hands. The stock had previously closed at $15.17.
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on PAYS. Lake Street Capital boosted their price target on Paysign from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, September 15th. DA Davidson upped their price objective on Paysign from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, September 30th. Wall Street Zen lowered Paysign from a “strong-buy” rating to a “buy” rating in a research note on Sunday, August 16th. Weiss Ratings raised Paysign from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. Finally, Barrington Research set a $15.00 price objective on Paysign in a research report on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $15.00.
Read Our Latest Research Report on Paysign
Paysign Stock Performance
Paysign (NASDAQ:PAYS – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.05. The company had revenue of $28.25 million during the quarter, compared to the consensus estimate of $26.36 million. Paysign had a net margin of 15.67% and a return on equity of 30.13%. Paysign has set its FY 2026 guidance at 0.350-0.370 EPS and its Q3 2026 guidance at 0.090-0.100 EPS. As a group, equities analysts predict that Paysign, Inc. will post 0.58 EPS for the current fiscal year.
Insider Activity at Paysign
In other Paysign news, CFO Jeffery Baker sold 35,000 shares of Paysign stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $12.62, for a total value of $441,700.00. Following the transaction, the chief financial officer owned 542,171 shares in the company, valued at $6,842,198.02. This trade represents a 6.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Michael C. Ngo sold 79,925 shares of the business’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $12.74, for a total transaction of $1,018,244.50. Following the sale, the insider directly owned 2,350,000 shares of the company’s stock, valued at $29,939,000. This represents a 3.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 444,904 shares of company stock worth $5,328,124. Company insiders own 24.50% of the company’s stock.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new position in Paysign in the second quarter valued at approximately $25,219,000. Punch & Associates Investment Management Inc. acquired a new position in Paysign during the second quarter valued at approximately $16,983,000. AWM Investment Company Inc. purchased a new stake in Paysign during the second quarter worth approximately $6,560,000. Renaissance Technologies LLC grew its stake in Paysign by 17.4% during the first quarter. Renaissance Technologies LLC now owns 1,531,072 shares of the company’s stock worth $9,033,000 after buying an additional 227,300 shares during the period. Finally, Bank of New York Mellon Corp purchased a new stake in Paysign during the second quarter worth approximately $1,629,000. 25.89% of the stock is owned by hedge funds and other institutional investors.
About Paysign
Paysign, Inc (NASDAQ: PAYS) provides prepaid payment and financial technology solutions, with a focus on healthcare, pharmaceutical and other specialized markets. Its platform supports the issuance and management of prepaid cards, digital payments, account services and related payment-processing activities.
The company’s healthcare offerings include patient assistance and copay programs that help pharmaceutical manufacturers distribute financial support to eligible patients. Paysign also provides payment and card solutions for plasma collection centers, including programs used to compensate plasma donors.
Featured Stories
- Five stocks we like better than Paysign
- A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
Receive News & Ratings for Paysign Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paysign and related companies with MarketBeat.com's FREE daily email newsletter.
